{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:35:57Z","timestamp":1767339357927,"version":"3.44.0"},"reference-count":47,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,1,19]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>We present a case study of a 61-year-old Vietnamese woman who presents with features of dermatomyositis (DM), including Gottron\u2019s papules, heliotrope rash, cutaneous ulcers, generalised weakness and pain, and weight loss with normal levels of creatine kinase (CK). She demonstrated features of interstitial lung disease and subsequently tested positive for anti-melanoma differentiation-associated gene 5 and anti-small ubiquitin-like modifier 1 activating enzyme antibodies, which belong to a DM subtype known as clinically amyopathic dermatomyositis and do not present with raised CK. She received standard treatment for DM, including oral prednisolone, hydroxychloroquine, mycopheonlate and topical betamethasone. The treatment successfully reversed skin changes; however, the patient remained generally weak and unable to carry out her activities of daily living.<\/jats:p>","DOI":"10.1136\/bcr-2019-232260","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T04:54:15Z","timestamp":1581051255000},"page":"e232260","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["A rare form of dermatomyositis associated with muscle weakness and normal creatine kinase level"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-4370","authenticated-orcid":false,"given":"Christopher","family":"Kwan","sequence":"first","affiliation":[{"name":"Department of General Medicine, Princess Alexandra Hospital Health Service District, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzana","family":"Milosevic","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Princess Alexandra Hospital Health Service District, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Benham","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Princess Alexandra Hospital Health Service District, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Princess Alexandra Hospital Health Service District, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.1","DOI":"10.1002\/art.21023"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.2","DOI":"10.1016\/j.jaad.2010.09.016"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.3","DOI":"10.1002\/art.24621"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.4","DOI":"10.1073\/pnas.0606699104"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.5","DOI":"10.1002\/art.1780291109"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.6","DOI":"10.1038\/nature04734"},{"key":"2025082709051703000_13.2.e232260.7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1590\/abd1806-4841.20186803","article-title":"Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis","volume":"93","author":"Borges","year":"2018","journal-title":"An Bras Dermatol"},{"key":"2025082709051703000_13.2.e232260.8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011024","article-title":"Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission","volume":"97","author":"Endo","year":"2018","journal-title":"Medicine"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.9","DOI":"10.1002\/art.22862"},{"key":"2025082709051703000_13.2.e232260.10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.11","DOI":"10.1016\/j.bbamcr.2004.09.021"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.12","DOI":"10.1034\/j.1600-0854.2002.30601.x"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.13","DOI":"10.1002\/hep.20619"},{"key":"2025082709051703000_13.2.e232260.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"7","author":"Ge","year":"2017","journal-title":"Sci Rep"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.15","DOI":"10.3109\/08916934.2012.755958"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.16","DOI":"10.1136\/ard.2008.097162"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.17","DOI":"10.1016\/j.jim.2012.07.019"},{"key":"2025082709051703000_13.2.e232260.18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10067-018-4267-z","article-title":"Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies","volume":"38","author":"Zampeli","year":"2019","journal-title":"Clin Rheumatol"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.19","DOI":"10.1006\/clin.1997.4412"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.20","DOI":"10.1097\/00005792-197707000-00001"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.21","DOI":"10.1097\/MD.0b013e3182606f0b"},{"key":"2025082709051703000_13.2.e232260.22","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-Melanoma differentiation\u2013associated gene 5 (MDA5) dermatomyositis: a Concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J Am Acad Dermatol"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.23","DOI":"10.1093\/rheumatology\/kel311"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.24","DOI":"10.3899\/jrheum.090061"},{"key":"2025082709051703000_13.2.e232260.25","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/jdv.12300","article-title":"Anti-MDA5 positive clinically amyopathic dermatomyositis presenting with severe cardiomyopathy","volume":"28","author":"Pau-Charles","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082709051703000_13.2.e232260.26","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s10067-019-04562-w","article-title":"Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review","volume":"38","author":"Jia","year":"2019","journal-title":"Clin Rheumatol"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.27","DOI":"10.7326\/0003-4819-84-1-68"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.28","DOI":"10.1111\/j.1749-6632.2009.05119.x"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.29","DOI":"10.1093\/rheumatology\/kep078"},{"key":"2025082709051703000_13.2.e232260.30","first-page":"207","article-title":"Survival in polymyositis: corticosteroids and risk factors","volume":"4","author":"Carpenter","year":"1977","journal-title":"J Rheumatol"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.31","DOI":"10.1016\/S0190-9622(96)90037-7"},{"key":"2025082709051703000_13.2.e232260.32","doi-asserted-by":"crossref","DOI":"10.2165\/00128071-200607060-00002","article-title":"Management of cutaneous dermatomyositis: current therapeutic options","volume":"7","author":"Quain","year":"2006","journal-title":"Am J Clin Dermatol"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.33","DOI":"10.1002\/mus.10026"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.34","DOI":"10.1093\/rheumatology\/kel336"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.35","DOI":"10.1212\/01.wnl.0000208416.32471.c0"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.36","DOI":"10.1093\/rheumatology\/keh499"},{"key":"2025082709051703000_13.2.e232260.37","first-page":"1214","article-title":"The treatment of dermatomyositis with hydroxchloroquine","volume":"12","author":"James","year":"1985","journal-title":"J Rheumatol"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.38","DOI":"10.1001\/archderm.1995.01690240035006"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.39","DOI":"10.1016\/S0190-9622(98)70496-7"},{"key":"2025082709051703000_13.2.e232260.40","first-page":"1545","article-title":"Adjunctive use of hydroxychloroquine in childhood dermatomyositis","volume":"16","author":"Olson","year":"1989","journal-title":"J Rheumatol"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.41","DOI":"10.1056\/NEJM199312303292704"},{"key":"2025082709051703000_13.2.e232260.42","first-page":"89","article-title":"Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin","volume":"62","author":"Peake","year":"1998","journal-title":"Cutis"},{"doi-asserted-by":"publisher","key":"2025082709051703000_13.2.e232260.43","DOI":"10.1136\/ard.2006.058644"},{"key":"2025082709051703000_13.2.e232260.44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1346-8138.1999.tb02026.x","article-title":"Low-Dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions","volume":"26","author":"Sadayama","year":"1999","journal-title":"J Dermatol"},{"key":"2025082709051703000_13.2.e232260.45","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2013.06.007","article-title":"Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center","volume":"69","author":"Femia","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2025082709051703000_13.2.e232260.46","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/jdv.12223","article-title":"Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease","volume":"28","author":"Bounfour","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082709051703000_13.2.e232260.47","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:05:26Z","timestamp":1756310726000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,6]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/bcr-2019-232260"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232260","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}